Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene following lymphodepleting conditioning for therapy-resistant esophageal cancer

Trial Profile

Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene following lymphodepleting conditioning for therapy-resistant esophageal cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs TBI 1201 (Primary) ; Cyclophosphamide
  • Indications Oesophageal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
    • 20 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top